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Abstract
Hepatocellular Carcinoma (HCC) is the fifth most common cancer worldwide. b-Catenin, the central orchestrator of the
canonical Wnt pathway and a known oncogene is paramount in HCC pathogenesis. Administration of phenobarbital (PB)
containing water (0.05% w/v) as tumor promoter following initial injected intraperitoneal (IP) diethylnitrosamine (DEN)
injection (5 mg/gm body weight) as a tumor inducer is commonly used model to study HCC in mice. Herein, nine fifteen-day
male b-catenin knockout mice (KO) and fifteen wild-type littermate controls (WT) underwent DEN/PB treatment and were
examined for hepatic tumorigenesis at eight months. Paradoxically, a significantly higher tumor burden was observed in KO
(p,0.05). Tumors in KO were b-catenin and glutamine synthetase negative and HGF/Met, EGFR & IGFR signaling was
unremarkable. A significant increase in PDGFRa and its ligand PDGF-CC leading to increased phosphotyrosine-720-PDGFRa
was observed in tumor-bearing KO mice (p,0.05). Simultaneously, these livers displayed increased cell death, stellate cell
activation, hepatic fibrosis and cell proliferation. Further, PDGF-CC significantly induced hepatoma cell proliferation
especially following b-catenin suppression. Our studies also demonstrate that the utilized DEN/PB protocol in the WT
C57BL/6 mice did not select for b-catenin gene mutations during hepatocarcinogenesis. Thus, DEN/PB enhanced HCC in
mice lacking b-catenin in the liver may be due to their ineptness at regulating cell survival, leading to enhanced fibrosis and
regeneration through PDGFRa activation. b-Catenin downregulation also made hepatoma cells more sensitive to receptor
tyrosine kinases and thus may be exploited for therapeutics.
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Introduction
Hepatocellular Carcinoma (HCC) is the fifth most common
cancer and the third cause of cancer death worldwide [1]. There is
a strong need to delineate the molecular alterations responsible for
the initiation and exacerbation of this disease. In order to study the
cellular and molecule perturbations in HCC, many preclinical
strategies employ the use of genetic and chemical models of
carcinogenesis. Administration of diethylnitrosamine (DEN) alone
or in conjunction with phenobarbital (PB) in mice is frequently
used to induce HCC in mice.
One pathway of critical importance in HCC is the Wnt/b-
catenin signaling. b-Catenin is the central effector of the canonical
Wnt signaling, which is a highly conserved pathway regulating
critical cellular processes such as proliferation, differentiation,
survival and self-renewal [2,3,4,5]. In the absence of Wnt, b-
catenin is phosphorylated at amino-terminal serine and threonine
residues and targeted for ubiquitination [6]. Upon binding of Wnt
protein to its cell surface receptor Frizzled and co-receptor low-
density lipoprotein– related protein 5/6 (LRP5/6), a signal is
transduced through disheveled that allows for inactivation of
degradation complex comprised of glycogen synthase kinase 3b
(GSK3b), adenomatous polyposis coli gene product (APC) and
casein kinase Ia, which allows b-catenin to dissociate and
translocate to the nucleus to bind to lymphoid enhancer-binding
factor/T cell factor (LEF/TCF) family of proteins to transactivate
target genes. The Wnt/b-catenin pathway has been implicated in
a subset of HCC where activating mutations in the b-catenin gene
(CTNNB1) have been reported in 20%–40% of patients [7,8].
Knockdown of b-catenin in hepatoma cells leads to decreased
growth and survival. For the aforementioned reasons, b-catenin is
a well-recognized oncogene and considered a valuable therapeutic
target.
With this background, we hypothesized that lack of b-catenin in
hepatocytes might protect against chemical-induced carcinogen-
esis especially in a model where HCC is conceived through tumor
induction by DEN and tumor promotion through the continuous
use of PB [9,10]. We used male conditional hepatocyte-specific b-
catenin knockout (KO) mice and sex-matched wild-type littermate
controls (WT) to study tumorigenesis in response to DEN/PB. We
report a paradoxical increase in hepatic tumorigenesis in the
absence of b-catenin that was attributable to enhanced injury,
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fibrosis and ensuing regeneration, which appear to be driven by a
rather non-classical epithelial receptor tyrosine kinase receptor
PDGFRa. We also demonstrate that utilizing the commonly
employed DEN/PB protocol in C57BL/6 mice, the tumorigenesis
does not occur through b-catenin mutations as is observed in C3H
mice. Lastly, b-catenin inhibition lead to PDGFRa activation and
thus may make the hepatoma cells more amenable to receptor
tyrosine kinases inhibition for therapies.
Results
b-Catenin loss in hepatocytes engenders enhanced
hepatocarcinogenesis in mice in response to DEN/PB
WT and KO male mice (C57BL/6) were given a single dose
(5 mg/gram) of DEN injection at postnatal day 14 days and two
weeks later allowed ad libitum access to PB containing drinking
water for 8 months at which time mice were examined for liver
tumors (Fig. 1A). Intriguingly, the mice lacking b-catenin in
hepatocytes displayed significantly enhanced tumorigenesis than
WT mice that was grossly appreciable as larger and greater
numbers of tumors (Fig. 1B). H&E staining was employed to also
determine the microscopic tumor foci in both groups of animals
(Fig. 1C). The total numbers of foci were counted in representative
sections from four lobes from the KO and WT, which show
significantly more tumors in KO as compared to the WT (p,0.05)
(Fig. 1D).
b-Catenin KO livers after DEN/PB treatment shows
increased cell death, stellate cell activation and fibrosis
and tumor proliferation
Next, we addressed the cellular mechanisms that may be the
basis of enhanced tumorigenesis in KO. We identify higher
numbers of TUNEL-positive hepatocytes in KO at 8 months after
DEN/PB as compared to similarly treated WT, suggesting greater
cell death (Fig. 2A). There was an accompanying increase in
hepatic parenchymal cell proliferation in KO that exceeded that of
WT (Fig. 2A). In addition, KO mice exhibited a dramatic increase
in the numbers of a-smooth muscle actin, which identifies
activated stellate cells that are responsible for collagen deposition
and fibrosis (Fig. 2A). Concomitant to stellate cell activation, we
observed enhanced fibrosis by Masson Trichrome staining in the
KO as compared to the WT (Fig. 2B). In fact only one of the 15
WT animals after DEN/PB challenge showed fibrosis, which was
comparable to fibrosis in the KO. All together, our results suggest
that greater tumorigenesis in KO livers was associated with
significantly greater cell death and proliferation (Fig. 2C), and
hepatic fibrosis as well.
Tumors in KO livers after DEN/PB are not composed of b-
catenin-positive hepatocytes
Since there have been reports from our lab and others that in
response to specific injuries, there is pressure on hepatocytes that
may have escaped cre-mediated deletion, our first goal was to
ascertain if livers exposed to DEN/PB from KO group showed
any reappearance of b-catenin especially when compared to the
WT. A representative WB showed that all KO livers from DEN/
PB exposed mice expressed dramatically lower levels of b-catenin
as compared to WT by western blots (Fig. 3A). This was also
verified by a detailed immunohistochemical analysis included in a
forthcoming section (Table 1 and Fig. 4). The low level of b-
catenin in KO livers represents its presence in the non-
parenchymal cells of the liver that show no albumin cre-mediated
recombination. Similarly analysis presented from representative
KO and WT livers also showed absence of glutamine synthetase, a
surrogate target gene of b-catenin signaling in the KO (Fig. 3A).
Cyclin-D1, another prominent target of b-catenin in liver and
elsewhere was increased in most WT, whereas 8/9 KO showed
very low or absent cyclin-D1 in response to DEN/PB (Fig. 3A and
not shown). C-Myc, another target of b-catenin, was ironically
higher in KO as compared to WT mice after DEN/PB exposure
as shown in a representative western blot (Fig. 3A). Thus KO livers
after DEN/PB continue to be negative for b-catenin after 8
months.
Tumors in KO livers after DEN/PB are not associated with activation of
traditional HCC associated receptor tyrosine kinases. Due to a paradoxical
increase in DEN/PB-induced tumorigenesis in KO, we next
explored possible molecular mechanisms. Both epidermal growth
factor (EGF) signaling and hepatocyte growth factor (HGF)
signaling are critical players in the development and exacerbation
of HCC [11]. We explored both total and phosphorylated status of
receptors of these receptor tyrosine kinases (RTKs) in livers from
DEN/PB-treated KO and WT mice. Interestingly we noted a
decrease in total and phosphorylated levels of c-Met, the HGF
receptor in KO animals as compared to WT (Fig. 3B). Both total
and phosphorylated levels of EGFR between WT and KO animals
remain unaltered (Fig. 3B). We also examined insulin like growth
factor receptor, another signaling pathway implicated in HCC
[11]. We noted higher levels of its phosphorylation in the WT as
compared to KO (Fig. 3B). Thus, classical RTKs do not appear to
be responsible for enhanced HCC in KO but p-Met and P-IGFR
are prominently induced in tumor bearing WT mice indicating
their important role in HCC.
Immunohistochemical characterization of KO and WT
liver tumors for b-catenin and PDGFRa
We next characterized the tumors observed in the WT and KO
by immunohistochemistry for b-catenin localization. Around 31%
of total tumor foci in WT mice showed nuclear b-catenin (Table 1,
Fig. 4). Out of 63 observed foci in 9 KO mice, only two were
composed of b-catenin-positive tumor cells that exhibited its
nuclear/cytoplasmic localization (data not shown) while others
were negative (Fig. 4). This substantiated the observations in
Fig. 3A and also demonstrates that almost all tumors in this group
were comprised by b-catenin-negative hepatocytes and cannot be
due to expansion of cells, which may have retained b-catenin due
to incomplete albumin-cre recombination.
We next investigated PDGFRa signaling, which has been
implicated in HCC and is involved in tumor growth, angiogenesis,
and maintenance of tumor microenvironment [12,13,14]. 54.5%
of all tumor foci in the WT mice showed cytoplasmic PDGFRa
expression (Table 1). We found around 94% of tumor foci in KO
to be strongly positive for PDGFRa in the cytoplasm of tumor cells
(Table 1, Fig. 4). Only four foci were negative for PDGFRa. The
two tumor foci that were b-catenin-positive in the KO livers were
simultaneously positive for PDGFRa.
In an additional analysis, 9 of the 55 tumors observed in the WT
were concomitantly positive for both PDGFRa and nuclear b-
catenin, while others were positive for either one of the two
(Table 1, Fig. 4). A small fraction of tumors were negative for both
these proteins. The two tumors that were composed of b-catenin-
positive hepatocytes in the KO were also positive for PDGFRa
signaling (Table 1). Overall, PDGFRa expression was higher and
also in greater numbers of tumor foci in the KO as compared to
the WT 8 months after DEN/PB exposure.
DEN/PB induced increased tumorigenesis is associated with activation of
PDGFRa signaling. To further verify PDGFRa increase in the KO
over WT after DEN/PB, we utilized western blots analysis.
b-Catenin Loss Promotes Chemical-Induced HCC
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PDGFRa protein levels were higher in the KO than the WT livers
(Fig. 5A), and this difference was statistically significant (Fig. 5B).
There was a modest increase in PDGFRb levels in the KO livers
(Fig. 5A). We also identified a noteworthy increase in total protein
levels of selective PDGFRa ligand PDGF-CC while PDGF-AA or
PDGF-BB remained unaltered between the two groups (Fig. 5C).
To determine consequences of enhanced PDGF-CC/PDGFRa
levels in KO we assessed levels of PDGFRa phosphorylation at
several specific tyrosine residues using antibodies listed in methods.
As shown in densitometric analyses, a significant increase in
Tyr720-PDGFRa (p,0.05) (Fig. 5D) but not in Tyr849-PDGFRa
(Fig. 5E) or Tyr572/574- and Tyr754-PDGFRa (not shown) was
observed in the KO. These observations demonstrate PDGFRa
activation in KO, which may be playing an important role in
hepatocarcinogenesis.
PDGFRa ligand stimulates hepatoma cell proliferation
only upon b-catenin suppression
To further ascertain the relevance of PDGFRa signaling in
absence of b-catenin, we utilized human hepatoma cells. PDGF-
CC was unable to induce any significant increase in Hep3B cell
DNA synthesis when compared to HCl, which was utilized to
reconstitute PDGF in almost confluent cell cultures (Fig. 6). b-
Catenin knockdown when compared to control siRNA transfec-
tion, significantly lowered thymidine incorporation in Hep3B cells
(p,0.0005) (Fig. 6). Only upon b-catenin silencing, was PDGF-
CC treatment able to induce significant DNA synthesis in Hep3B
cells as compared to HCl (p,0.005). Thus b-catenin suppression
enabled PDGF-CC to be mitogenic to Hep3B cells.
Figure 1. Enhanced tumorigenesis in b-catenin KO mice exposed to DEN/PB regimen. Experimental strategy summarizing DEN/PB
treatment in KO and WT mice. A. Representative photographs of tumor-bearing livers in DEN/PB treated KO and WT mice at the time of harvest at 8
months of age. B. DEN/PB induced microscopic tumor foci (outlined by arrowheads) visualized by H&E in WT and KO livers at 8 months of age. C. A
significant increase in microscopic tumor foci in KO as compared to WT (p,0.05). Tumors were counted from H&E stained sections representing 4
liver lobes from each KO and WT animals on DEN/PB protocol.
doi:10.1371/journal.pone.0039771.g001
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Discussion
To understand the molecular and cellular basis of HCC in
patients, several preclinical models are in use including DEN or
DEN/PB regimens in rodents. DEN is a commonly used
carcinogen to induce HCC in rodent models, however it has high
strain specificity. In C57BL/129Sv6C3H/He mice, a strain more
susceptible to hepatocarcinogenesis, DEN injection at around 6
weeks of age at a dose of 90 mg/gm body weight, induces HCC
through Ha-Ras mutations, while inclusion of PB in drinking
water after 3 weeks of DEN, promotes tumorigenesis due to
CTNNB1 mutations. [15]. However, another study in male
B6C3F1 mice, obtained by interbreeding female C57BL/6J and
male C3H/HeJ mice, injected DEN at 10 mg/gm body weight at 3
weeks of age without PB, showed HCC via CTNNB1 mutations
[16]. Another model utilizes DEN at a dose of 5 mg/gm body in
C57BL/6 mice, a strain relatively resistant to HCC. Here, DEN
induces DNA adducts in hepatocytes undergoing cell division, and
eventually leads to development of HCC [17,18]. Inclusion of PB
enhances tumorigenesis via its tumor promoting ability [9,10]. In
Figure 2. Tumorigenesis in KO mice following DEN/PB treatment is associated with greater injury, fibrosis and regeneration. A.
Representative tumor-bearing KO livers show increased parenchymal cell death (TUNEL), greater stellate cell activation (a-SMA) and increased
parenchymal cell proliferation (PCNA) as compared to WT. B. Increased hepatic fibrosis (blue) in tumor-bearing KO livers is evident by Masson
Trichrome staining as compared to control. C. PCNA- and TUNEL-positive cells were counted in 4 random sections of 5 representative KO and WT
livers. A significant increase in both PCNA and TUNEL positive parenchymal cells was evident in KO livers as compared to WT after DEN/PB treatment.
doi:10.1371/journal.pone.0039771.g002
Figure 3. Molecular signaling in tumor-bearing KO and WT
mice. A. Representative western blot analysis from 5 WT and 4 KO
tumor-bearing livers shows low b-catenin, absent GS and dramatically
lower cyclin-D1 in KO whereas c-Myc levels were increased. Actin
verifies equal loading. B. Examination of RTK in the same sets of animals
shows notably lower phospho-Met and phospho-IGFR and only
marginally lower phospho-EGFR, in KO than WT livers by western
blots. GAPDH verifies comparable loading.
doi:10.1371/journal.pone.0039771.g003
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our study, we show that unlike C57BL/129Sv6C3H/He mice,
DEN/PB induced liver tumors in the C57BL/6 mice did not
exhibit nuclear/cytoplasmic localization of b-catenin and hence
does not selectively cause HCC via CTNNB1 mutations. Thus
mouse strain consideration for studying tumorigenesis in response
to specific protocols is highly relevant.
Many pathways broadly categorized into Ras/MAPK,
PIK3CA/AKT, and Wnt/b-catenin signaling, have been shown
to be of significance in HCC [11,19]. b-Catenin, the central
orchestrator of Wnt signaling, is a known oncogene due to its
implications in a variety of cancers, including 20%–40% of all
HCCs [20]. Intriguingly though, overexpression of either wild-
type or mutant form of b-catenin in murine livers is unable to
induce spontaneous HCC [21,22,23,24]. However, in the
presence of another ‘hit’ in the form of a transgene or a chemical
carcinogen, these various mice show enhanced tumorigenesis
[23,25,26]. Paradoxically, conditional loss of b-catenin in hepa-
tocytes in C57BL/6 mice led to an unexpectedly higher
susceptibility to DEN-induced HCC [27]. Another group also
recently showed demonstrated increased tumorigenesis in KO
mice in response to DEN/PB, albeit in C3H/N mice [28]. In the
current study, we provide evidence that b-catenin KO mice in
C57BL/6 background subjected to DEN-mediated tumor induc-
tion at P14 followed by tumor promotion 2 weeks later by PB also
led to a dramatically higher tumor burden.
DEN or DEN/PB induced HCC in any strain of mice is not
typically associated with any hepatic fibrosis. However, in the b-
catenin conditional null mice DEN/PB exposure led to develop-
ment of HCC, which was associated with hepatic fibrosis and is in
line with recent studies by others and us [27,28]. We also saw an
increase in cell death and resulting increase in cell proliferation. In
fact we identified increased stellate cell activation, a modest
increase in PDGFRb and ensuing hepatic fibrosis. These data
indicate that b-catenin loss makes livers more prone to genotoxic
injury and eventually tumorigenesis mimicking the predominant
scenario of human HCC where tumors often occurs in cirrhotic
background [29]. Role of b-catenin in regulating redox state has
been implied in many recent studies where its interactions with
HIF1a, FOXO3 and others may be critical [30,31]. It will thus be
important to understand the basis of such ‘tumor suppressive’ roles
of b-catenin in HCC that may eventually require careful selection
of patients to be treated with anti-b-catenin therapies [32].
To ascertain the molecular basis of HCC in the absence of b-
catenin, we were interested in signaling pathways that are well
known in the development and exacerbation of HCC. C-Met and
IGFR phosphorylation was increased in WT but not in KO mice
while EGFR activation was only mildly elevated in WT. Thus
while these RTK’s may be playing an important role in
tumorigenesis in the WT exposed to DEN/PB, their participation
in KO is unlikely. Based on our previous findings in DEN-induced
tumorigenesis in KO [27] and independent studies showing an
important role of PDGFR signaling in HCC [12,13,14], we
investigated its expression and activation in DEN/PB studies.
PDGFRa levels were significantly upregulated in KO after DEN/
PB-exposure. In addition, PDGF-CC a selective ligand of
PDGFRa, whose overexpression in liver-specific transgenic mice
has been shown to induce cirrhosis and HCC [33], was also
increased in KO. In fact PDGF-CC was localized to hepatocytes
in KO exposed to DEN/PB (data not shown) suggesting an
autocrine loop of signaling. The results obtained from thymidine
incorporation assay in the Hep3B cells, corroborates in vivo
findings. While decreased cell proliferation was observed in
hepatoma cells after b-catenin knockdown [34], PDGF-CC
promoted their mitogenesis more robustly only after b-catenin
suppression that leads to PDGFRa upregulation [27]. This also
verifies PDGFRa signaling as a means of escape from b-catenin
therapeutic inhibition.
PDGFRa overexpression in the presence of increased PDGF-
CC led to increased Tyr720-PDGFRa in tumor bearing KO but
not WT livers after DEN/PB. Phosphorylation at tyrosine 720 is
known to activate phosphatase SHP2, which in turn dephosphor-
ylates Src, leading to its activation [35]. Src activation has been
shown to induce c-Myc, an important proto-oncogene [36], which
was concomitantly elevated in KO. Other tyrosine sites in
PDGFRa showed inconspicuous changes in phosphorylation
between the KO and WT and thus may be of lesser relevance
in the current tumorigenesis model.
Only around 3% of all tumors in the 9 KO’s at 8 months after
the DEN/PB regimen were b-catenin-positive tumors that may be
due to ‘leaky’ cre-recombinase. b-Catenin-negative tumors were
also negative for GS and mostly negative for cyclin-D1. We have
not followed any animals in this study beyond 8 months. Others
have recently reported extensive spontaneous repopulation in KO
livers albeit at 18–20 months of age [37]. One group has reported a
more robust spontaneous repopulation and hepatic adenomatosis
in KO, which has not been reported by any other group working
Figure 4. b-Catenin and PDGFRa immunohistochemistry in
tumors in WT and KO exposed to DEN/PB. Tumors in WT were
heterogeneous and were either positive for both b-catenin and
PDGFRa, or for either one of them. In KO, almost all tumors lacked
any b-catenin and showed intense PDGFRa-positivity.
doi:10.1371/journal.pone.0039771.g004
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with the b-catenin conditional knockout mice [38]. The only
instance of extensive repopulation in the KO mice in our
experience was observed after continuous administration of diet
containing 0.1% 3,5-diethoxycarbonyl-1,4-dihydrocollidine
(DDC) for 5 months [39]. In fact KO mice have been studied
after partial hepatectomy, methionine-choline deficient diet,
alcohol diet or DEN and have exhibited lack of hepatic
repopulation with b-catenin-positive hepatocytes [27,31,40,41].
Materials and Methods
Animal studies
All animal experiments were performed under the guidelines of
the National Institutes of Health and the Institutional Animal Use
and Care Committee at the University of Pittsburgh. The studies
performed in the current report were approved by the Institutional
Animal Use and Care Committee at the University of Pittsburgh.
Mice with conditional deletion of b-catenin in hepatocytes with
genotype- Ctnnb1loxp/loxp;Alb-Cre+/2 are refered to as knockout
mice (KO) and have been described previously [41]. Littermates
with any of the following genotypes- Ctnnb1loxp/loxp;Alb-Cre2/2,
Ctnnb1loxp/WT;Alb-Cre+/2, Ctnnb1loxp/WT;Alb-Cre2/2 are re-
ferred to as wild-type or WT. These mice are in C57BL/6
background.
Male KO (n= 9) and WT (n= 15) mice were injected
intraperitoneally with DEN (Sigma-Aldrich, Inc.) at a dose of
5 mg/gram body weight at postnatal day 14 and from day 28
onwards the drinking water available ad libitum contained
phenobarbital (PB) (0.05% w/v). Water containing fresh PB was
prepared weekly for the duration of the studies. Mice were
sacrificed at 8 months and liver collected for histology and protein
analysis.
Western blot Analysis: Total tissue lysates prepared in radio
immuno-precipitation assay (RIPA) buffer containing 1% IgePAL
CA-630, 0.5% Sodium Deoxycholate, 0.1% SDS in 16PBS along
with protease & phosphate inhibitor (1:100) (Thermo Scientific).
Proteins were resolved on sodium dodecyl sulfate polyacrylamide
gel electrophoresis in 4–15% gels and then transferred to
Immobilon-P membranes (Millipore, Bedford, MA) in transfer
buffer containing 10% methanol. Membranes were probed with
primary antibodies (see below) in Tris-buffered saline with Tween-
20 containing 5% nonfat milk or BSA. Horseradish peroxidase–
conjugated secondary antibodies were used at 1:50,000 dilution
and signal assessed with Super Signal West Pico chemilumines-
cence substrate (Pierce, Rockford, IL) and autoradiography. The
Table 1. Summary of immunohistochemical findings of microscopic tumor foci for b-catenin and PDGFRa.
SAMPLE
NUMBER OF TUMOR
FOCI
b-CATENIN-POSITIVE
FOCI
PDGFRa-POSITIVE
FOCI
NUMBER OF FOCI POSITIVE FOR
BOTH N/C FIGURE 4
N/C M C b-CATENIN & PDGFRa
WT1 2 0 1 0 0
WT2 2 0 0 2 0
WT3 0 0 0 0 0
WT4 4 4 3 2 2
WT5 0 0 0 0 0
WT6 9 2 1 6 1
WT7 2 0 1 0 0
WT8 6 5 5 3 3
WT9 4 1 4 1 0 X
WT10 2 2 2 2 2 X
WT11 6 0 6 4 0
WT12 2 0 2 1 0
WT13 2 1 2 2 1
WT14 11 2 8 7 1 X
WT15 1 0 1 0 0
55 17 36 30 9
KO1 17 1 0 17 1 X
KO2 11 0 0 10 0
KO3 3 0 0 3 0 X
KO4 4 0 0 4 0
KO5 2 0 0 2 0
KO6 6 0 0 6 0
KO7 6 1 0 4 1
KO8 10 0 0 10 0
KO9 4 0 0 3 0
63 2 0 59 2
Abbreviations: WT-wildtype; KO-knockout; N/C- nuclear/cytoplasmic; M-membranous; C-cytoplasmic.
doi:10.1371/journal.pone.0039771.t001
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films (Molecular Technology Sales, St. Louise, MI) were scanned
to obtain integrated optic densitomery (IOD) using NIH Imager
software. The average IOD for a protein was compared between
the KO and WT groups and assessed for statistical significance by
student t test and p,0.05 was considered significant.
Antibodies. Primary antibodies used for Western blotting includ-
ed: c-Met (1:500), phospho-Met Tyr1234/1235 (1:1000), EGFR
(1:1000), phospho-PDGFRa Tyr849 (1:1000), phospho-IGFR
(1:1000) all from Cell Signaling Technology; b-catenin (1:1000)
from BD Biosciences; PDGFRa (1:180), PDGFRb (1:500),
phospho-EGFR (1:500), phospho-PDGFRa Tyr720 (1:200), c-
myc (1:200), PDGFA (1:200), PDGFB (1:200), PDGFC (1:200),
phospho-PDGFRa Tyr754 (1:200), Glutamine Synthethase
(1:200), and GAPDH (1:1000) all from Santa Cruz Biotechnology;
phospho-PDGFRa Tyr572/574 (1:800, Invitrogen); Cyclin
D1(1:200, Neomarkers); alpha smooth muscle actin (1:300,
Abcam); and b-actin (1:2000, Millipore).
Histology and immunohistochemistry
Four-micron sections of paraffin-embedded liver tissues were
used for histology and immunohistochemical staining. Hematox-
ylin and Eosin (H&E) staining was employed to identify tumor
foci. Typically four representative lobes from each mouse were
included on each slide. Tumor foci were identified based on
characteristic attributes such as basophilic cytoplasm and mitotic
figures. For comparison, total number of microscopic nodules were
counted and average numbers compared for statistical significant
by student t test with p,0.05 considered significant.
For immunohistochemistry, antigen retrieval was achieved both
by steam cooking or boiling the slides in microwave in citrate
buffer for 20 minutes or 10 minutes, respectively. The sections
Figure 5. Tumor-bearing KOmice display active PDGFRa signaling when compared to WT. A. Representative western blots from 8 KO and
9 WT show a dramatic increase in total levels of PDGFRa and modest increase in PDGFRb in the KO. Actin loading verifies equal loading. B. Average
integrated optical density (IOD) obtained from scanned autoradiographs shown in Fig. 5A revealed significantly higher PDGFRa levels in KO
(p= 0.002). C. Western blot from representative samples shows a dramatic increase in PDGF-CC, a ligand for PDGFRa in KO whereas PDGF-AA and BB
remained unremarkable between the two groups. D. Bar graph depicts a significant increase in Tyr720-PDGFRa in KO as compared to WT (p,0.05). E.
Insignificant differences were evident in Tyr-849-PDGFRa between the WT and KO.
doi:10.1371/journal.pone.0039771.g005
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were inactivated for endogenous peroxide, blocked and incubated
with primary antibody overnight at room temperature or for one
hour at room temperature, washed and incubated with appropri-
ate biotin-conjugated secondary antibody for 30 minutes. Sections
were washed, incubated with ABC reagent, washed and incubated
with DAB. Sections were next counterstained with Shandon
hematoxylin solution (Sigma) and cover slipped using Cytoseal
XYL (Richard Allen Scientific, Kalamazoo, MI). For negative
control, the primary antibody was omitted in the protocol. Slides
were viewed under an Axioskop 40 (Zeiss) upright research
microscope and digital images obtained. Collages were prepared
using Adobe Photoshop CS4 software. For PCNA and TUNEL,
numbers of positive cells were counted in four random 4006 fields
in five representative livers from each group and averages
compared for significance between groups by student t test. P
value of less than 0.05 was considered significant. For quantitative
analysis of b-catenin- and PDGFRa-positivity in tumors, all
microscopic foci in KO and WT livers were assessed. Any tumor
foci showing cytoplasmic and/or nuclear b-catenin staining were
labeled as being b-catenin-positive and any foci exhibiting
cytoplasmic staining for PDGFRa as compared to surrounding
non-tumor areas were labeled as being PDGFRa-positive. This
enabled us to calculate percentage of b-catenin and/or PDGFRa-
positive tumors in each group after DEN/PB treatment.
Cell culture and treatment
Hep3B cells (ATCC) were grown to 100% confluence in 10%
FBS and EMEM media. Cells were trypsinized and plated in 6
well plates containing 2 ml of 10% FBS EMEMmedia and serum-
starved overnight. Transfection was performed using pre-validated
b-catenin and control siRNA (Ambion) using lipofectamine as
described previously [34]. 24 hours after transfection, cells were
treated with 10 ng/ml of recombinant PDGF-CC (R&D systems)
or HCl (used to reconstitute PDGF-CC) in 4% media containing
tritiated thymidine. After 24 hours, the media was discarded and
1 ml of 5% trichloroacetic acid (TCA) was added to each well and
plates placed in 4uC for 15 minutes. Cells were washed, dried and
suspended in 1 ml of 0.33 M NaOH for 20 minutes, and 300 ml of
total mixture from each well was added to 3 ml of scintillation
fluid and then placed in scintillation counter. Experiment was
repeated at least twice and each condition was done in triplicates.
Average counts per minute (CPM) were compared between
different conditions for statistical significance by student t test with
value of less than 0.05 considered significant.
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